Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Coronavirus disease of 2019 (COVID-19) is well known to increase the risk of developing venous thromboembolism; thus, patients with COVID-19 may present to neurologists with cerebral venous sinus thrombosis. We present a patient presenting acutely with delirium, who after initial negative viral testing, was diagnosed with cerebral venous sinus thrombosis in association with COVID-19.
A 50-year-old man presented with delirium. PCR nasopharyngeal swabs for the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) were negative but we made a diagnosis of probable COVID-19 based on clinical and radiological features according to European Centre for Disease Control case definition criteria.1 Fibrinogen was 3.8 g/L (1.8–5.4) and neutrophil:lymphocyte ratio 14.4; age ≥50 years and neutrophil:lymphocyte ratio ≥3.13 have been associated with severe disease.2 D-dimer was not recorded acutely. A non-contrast CT scan of head and CSF analysis on admission were normal. We started enoxaparin 40 mg once daily subcutaneously as prophylaxis for venous thromboembolism and he did not need ventilator support.
Despite clinical improvement, he had persisting problems with executive dysfunction and dyspraxia. Repeat CT scan of head and CT venogram 1 week following admission showed dural venous sinus thrombosis involving the whole of the superior sagittal sinus, left transverse sinus and left sigmoid sinus down to the level of the …
Twitter Elizabeth J Coulthard @LizCoulthard.
Acknowledgements We are grateful to the patient for permission to publish case report and to all members of the clinical team who were involved in patient care.
Contributors All authors contributed to data collection and analysis as well as drafting and review of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Consent obtained directly from patient(s).
Ethics approval Patient consent has been provided for publication of case report.
Provenance and peer review Not commissioned. Externally peer reviewed by David Werring, London, UK.
Data availability statement All data relevant to the study are included in the article.
Read the full text or download the PDF:
Other content recommended for you
- Cerebral venous thrombosis: a practical guide
- Intracranial venous thrombosis in a man taking clomiphene citrate
- Extensive cerebral venous sinus thrombosis: a potential complication in a patient with COVID-19 disease
- Management and outcome of spontaneous cerebral venous sinus thrombosis in a 5-year consecutive single-institution cohort
- Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis
- Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination
- Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review
- Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases
- Sagittal sinus thrombosis with subarachnoid haemorrhage in a patient with COVID-19 infection
- Cerebral venous sinus thrombosis after ChAdOx1 vaccination: the first case of definite thrombosis with thrombocytopenia syndrome from India